PF-03382792 (PF-3382792) is a clinical compound under phase 1 investigation for an unknown indication..

PF-03049423 is a potent, selective, orally active, and brain penetrant inhibitor of PDE5 with IC50 of 0.2 nM.

PF-02575799 is a highly potent microsomal triglyceride transfer protein (MTP) inhibitor with IC50 of 0.77 nM.

PF-02413873 (PF-2413873) is a potent, selective, fully competitive, and orally active progesterone receptor (PR) antagonist with Ki of 9.7 nM.

PF-00610355 (PF 610355) is a potent, selective, and long-acting β2-adrenoreceptor agonist with EC50 of 0.26 nM.

PF 5212372 (PLA-950, ZPL-521, ZPL 5212372) is a potent, selective inhibitor of cPLA2 (cytosolic phospholipase A2α) with IC50 of 7 nM.

PF 4800567 is a selective casein kinase 1ε inhibitor; displays 22-fold greater potency towards CK1ε than CK1δ (IC50 values are 32 and 711 nM for CK1ε and CK1δ respectively).

PF 03709270 is an orally available ester prodrug form of sulopenem, with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria.

Petroselinic acid, a positional isomer of oleic acid, is isolated from the vegetable oil of Coriandrum sativum fruits.

Perlapine (AW-14233.

Perisesaccharide C is an oligosaccharide isolated from the root barks of Periploca sepium.

Perisesaccharide B is an oligosaccharide isolated from the root barks of Periploca sepium.

Perindopril erbumine is a potent ACE inhibitor of which is used to treat high blood pressure, heart failure or stable coronary artery disease.

Perhexiline is a prophylactic antianginal agent that inhibits carnitine palmitoyltransferase (CPT1/CPT2).

Peptide Fz7-21 is a potent, selective peptide inhibitor of Frizzled 7 receptor, inhibits exogenous WNT3A stimulated Wnt-β-catenin signaling in HEK293 cells with IC50 of 100 nM.

Penicillamine (Cuprimine)

Pefloxacin mesylate

PDEδ-IN-99 is a novel potent K-Ras-PDEδ inhibitor that binds to the farnesyl binding pocket of PDEδ with Kd of 8±4 nM..

PDE4D-IN-26b is a potent, highly selective PDE4D inhibitor with IC50 of 0.6 nM, displays 75-fold lower activity against the PDE4A, B, and C subtypes, also exhibits 18,000-fold decreased potency against other PDE family members.

PDE2 inhibitor 4 is a potent, selective, orally available inhibitor of PDE2 with IC50 of 2 nM, displays high selectivity versus other PDE isoforms.

PDE10A-IN-32 is a potent, highly selective, brain penetrant PDE10A inhibitor with IC50 of 0.14 nM, displays no significant activity against other PDEs (IC50>1,000 nM)..

PDE10A-IN-31 is a potent, highly selective PDE10A inhibitor with IC50 of 2 nM for both rPDE10A and hPDE10A.

PD1-PD L1 inhibitor Polaris is a novel potent, small molecule inhibitor of PD-1/PD-L1 interaction (IC50=0.1-10 nM in ELISA assays) with anti-cancer activity.

PD1-IN-2 is a PD1 signaling pathway inhibitor, which acts as an immunomodulator.

PCSK9-IN-7l is a potent, small molecule PCSK9 mRNA translation inhibitor with IC50 of 1.37 uM, shows limited bone marrow toxicity (IC50=27.1 uM)..

PCSK9 modulator 10 is a highly potent, orally active PCSK9 modulator that inhibits PCSK9 production in HepG2 cells with IC50 of 0.036 nM.

PCI-33380 is an irreversible Bruton's Tyrosine Kinase (BTK) inhibitor (fluorescent probe).

PCARBTP is a derivative, potent, specific Kv1.3 channel inhibitor, reduces cell viability and efficiently kills B16F10 cancer cells at 1 uM.

PCAF BRD inhibitor L-45 is a potent, selective, and cell-active PCAF bromodomain inhibitor with Ki of 47 nM in HTRF assays, >4,500-fold selectivity over BRD4.

PC945 is a novel broad spectrum antifungal agent that potently inhibits Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B) with IC50 of 0.23 and 0.22 uM, respectively.